Suppr超能文献

持续性和复发性心肌梗死后室性心动过速的药物及手术治疗

Medical and surgical treatment of sustained and recurrent post-infarction ventricular tachycardia.

作者信息

Salerno J A, Bressan M A, Vigano M, Chimienti M, Previtali M, Martinelli L, Pagnin A, Montemartini C, Bobba P

出版信息

Eur Heart J. 1985 Dec;6(12):1054-62. doi: 10.1093/oxfordjournals.eurheartj.a061809.

Abstract

Over a five-year period 57 patients (pts) with sustained, recurrent, post-infarction ventricular tachycardia (VT) refractory to conventional antiarrhythmic treatment were evaluated. In 28 (49%) pts VT was controlled by amiodarone (A) in a dose of 3000 mg week-1. During long-term follow-up 5/28 (18%) pts died; no severe side-effects were observed with this dosage. In 17 of the 29 pts not controlled by this regimen, the dosage of A was increased to 6000-8000 mg week-1; short-term control of VT was achieved in 9/17 (53%) pts, but over a long-term follow-up 5/9 (56%) died and severe side-effects (11% pulmonary fibrosis and 11% hepatitis) occurred in 22%. Twenty pts, resistant to a low (12 pts) or high (8 pts) doses of A, underwent map-guided surgical treatment. In conclusion A is superior to conventional drugs in the treatment of sustained, recurrent, post-infarction VT, but when high doses are necessary to prevent VT, long-term results are poor and severe side-effects frequent. In pts refractory to standard doses of A, map-guided surgery is the treatment of choice.

摘要

在五年期间,对57例持续性、复发性、心肌梗死后室性心动过速(VT)且对传统抗心律失常治疗无效的患者进行了评估。在28例(49%)患者中,胺碘酮(A)以每周3000毫克的剂量控制了VT。在长期随访中,28例中有5例(18%)死亡;该剂量未观察到严重副作用。在未被该方案控制的29例患者中的17例中,A的剂量增加到每周6000 - 8000毫克;9/17例(53%)患者实现了VT的短期控制,但在长期随访中,9例中有5例(56%)死亡,22%出现了严重副作用(11%为肺纤维化,11%为肝炎)。20例对低剂量(12例)或高剂量(8例)A耐药的患者接受了标测引导下的手术治疗。总之,在治疗持续性、复发性、心肌梗死后VT方面,A优于传统药物,但当需要高剂量来预防VT时,长期效果不佳且严重副作用频繁。对于对标准剂量A耐药的患者,标测引导下的手术是首选治疗方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验